HTLV-1 Associated Myelopathy Diagnosis
The diagnosis of HTLV-1 associated myelopathy (HAM/TSP) requires demonstration of HTLV-1 antibodies in both serum and cerebrospinal fluid, combined with characteristic clinical features of progressive spastic paraparesis, and exclusion of other myelopathies. 1
Clinical Presentation to Recognize
HAM/TSP presents with a distinctive pattern that differs from multiple sclerosis 1:
- Progressive, permanent lower-extremity weakness and spasticity (not waxing and waning)
- Hyperreflexia in the lower extremities
- Sensory disturbances affecting the legs
- Urinary incontinence or bladder dysfunction
- Cranial nerves are NOT involved (key distinguishing feature from MS)
- Cognitive function remains intact (unlike MS)
- Lower back pain may be present 2
The disease is more common in women and has a shorter latency period than HTLV-1-associated leukemia (median 3.3 years from transfusion-acquired infection) 1.
Diagnostic Algorithm
Step 1: Serological Testing
- Screen serum for anti-HTLV-1/2 antibodies using highly sensitive screening tests 3
- Confirmation and typing are essential to differentiate HTLV-1 from HTLV-2 using additional serological or molecular methods 3
- Approximately 25-30% of sex partners of infected individuals are also seropositive 1
Step 2: CSF Analysis (Critical for Diagnosis)
Antibodies to HTLV-1 are characteristically found in the cerebrospinal fluid 1. This is a defining feature of HAM/TSP.
- Detect intrathecal anti-HTLV-1 antibodies in CSF 3
- Quantify HTLV-1 provirus in CSF - provides additional diagnostic evidence, especially in atypical cases 3
- CSF testing is particularly important when alternative causes of neuroinflammation cannot be excluded 3
Step 3: Imaging
- MRI of the spinal cord to identify cord lesions and exclude alternative diagnoses 4
- In rapidly progressive cases, 98% show radiographic features of myelitis, with 93% demonstrating longitudinally extensive lesions 5
- MRI may show spinal cord atrophy in chronic cases
Step 4: Exclusion of Other Causes
Must rule out 6:
- Multiple sclerosis (look for waxing/waning course, cranial nerve involvement)
- Neuromyelitis optica
- Compressive myelopathy
- Metabolic causes (B12 deficiency, copper deficiency)
- Other infectious myelopathies
Diagnostic Criteria Levels
The diagnosis can be classified as 6:
Definite HAM/TSP:
- Characteristic myelopathic symptoms (progressive spastic paraparesis)
- HTLV-1 antibodies in serum AND CSF
- Detection of HTLV-1 DNA
- Exclusion of other disorders
Probable HAM/TSP:
- Myelopathic symptoms
- HTLV-1 antibodies in serum
- Exclusion of other disorders
Possible HAM/TSP:
- Incomplete clinical or laboratory findings
Emerging Biomarkers for Prognosis
While not required for diagnosis, these markers have prognostic value 3:
- CXCL10 (CXC motif chemokine ligand 10) in serum and CSF - emerging inflammatory marker
- Neopterin in serum and CSF - for monitoring and management
- Neurofilament light chain in CSF and blood - measures neurodegeneration and may contribute to prognosis
- HTLV-1 proviral load in peripheral blood - higher loads associated with disease development 7, 8
Critical Pitfalls to Avoid
Don't miss HAM/TSP in non-endemic areas: With globalization, consider this diagnosis even in regions like the northeastern United States 5, 8
Don't confuse with MS: The progressive, non-remitting course without cranial nerve involvement distinguishes HAM/TSP 1, 9
Don't skip CSF testing: Intrathecal antibodies are characteristic and essential for definitive diagnosis 1, 3
Consider rapidly progressive variants: While typically insidious, HAM/TSP can present acutely with longitudinally extensive myelitis 5
Screen high-risk populations: Those from endemic areas (Japan, Caribbean, South America, parts of Africa), history of blood transfusion before screening era, injection drug users, or sexual partners of infected individuals 1, 5
Risk Factors to Elicit in History
- Geographic origin: Japan, Caribbean, South America, sub-Saharan Africa
- Blood transfusion history (especially before HTLV screening)
- Breastfeeding from infected mother 10
- Sexual contact with infected partner
- Injection drug use (though HTLV-2 more common in this group) 1
- Pregnancy/postpartum period - may trigger or worsen disease 10